Oridonin induces G2/M cell cycle arrest and apoptosis through MAPK and p53 signaling pathways in HepG2 cells

Oncology Reports

Volumn 24, Issue 3, 2010, Pages 647-651

  Wang, Hui ^a   Ye, Yan ^a   Chu, Jian Hong ^a   Zhu, Guo Yuan ^a   Li, Ying Wei ^a   Fong, David W F ^a   Yu, Zhi Ling ^a  

^a HONG KONG BAPTIST UNIVERSITY   (Hong Kong)

Author keywords

Apoptosis; G2 M arrest; HepG2; MAPK; Oridonin; p53

Indexed keywords

4',6 DIAMIDINO 2 PHENYLINDOLE; CASPASE 3; CASPASE 9; CELL CYCLE PROTEIN 20; CYCLIN B1; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE 4; ORIDONIN; P21 ACTIVATED KINASE; PROTEIN P53;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL PROLIFERATION; CELL STRAIN HEPG2; CELL STRUCTURE; CELL VIABILITY; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DOSE RESPONSE; DRUG INHIBITION; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPE; HUMAN; HUMAN CELL; HUMAN TISSUE; IC 50; IMMUNOBLOTTING; LIVER CELL CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CASPASE 3; CASPASE 9; CELL CYCLE; CELL DIVISION; CELL SURVIVAL; CYCLIN B; CYCLIN B1; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DITERPENES, KAURANE; DOSE-RESPONSE RELATIONSHIP, DRUG; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; G2 PHASE; HEP G2 CELLS; HUMANS; INHIBITORY CONCENTRATION 50; JNK MITOGEN-ACTIVATED PROTEIN KINASES; LIVER NEOPLASMS; MAP KINASE SIGNALING SYSTEM; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; TIME FACTORS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 77956301155     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000903     Document Type: Article

References (19)

1. Farazi PA and DePinho RA: Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer 6: 674-687, 2006.
2. Luk JM, Wang X, Liu P, et al: Traditional Chinese herbal medicines for treatment of liver fibrosis and cancer: from laboratory discovery to clinical evaluation. Liver Int 27: 879-890, 2007.
3. Sun HD, Huang SX and Han QB: Diterpenoids from isodon species and their biological activities. Nat Prod Rep 23: 673-698, 2006. (Pubitemid 44455387)
4. Wang RL: Dong ling cao zhi liao yuan fa xing gan ai 31 li lin chuang guan cha. Ai Zheng 3: 50, 1984.
5. Zhang JF, Chen GH, Lu MQ and Liu JJ: Antiproliferation effects of oridonin on hepatocellular carcinoma BEL-7402 cells and its mechanism. Chinese Traditional Patent Medicine 28: 1325-1329, 2006.
6. Huang J, Wu L, Tashiro S, Onodera S and Ikejima T: Reactive oxygen species mediate oridonin-induced HepG2 apoptosis through p53, MAPK, and mitochondrial signaling pathways. J Pharmacol Sci 107: 370-379, 2008.
7. Widmann C, Gibson S, Jarpe MB and Johnson GL: Mitogen-activated protein kinase: conservation of a three-kinase module from yeast to human. Physiol Rev 79: 143-180, 1999.
8. Wiesenauer CA, Yip-Schneider MT, Wang Y and Schmidt CM: Multiple anticancer effects of blocking MEK-ERK signaling in hepatocellular carcinoma. J Am Coll Surg 198: 410-421, 2004.
9. Wu GS: The functional interactions between the p53 and MAPK signaling pathways. Cancer Biol Ther 3: 156-161, 2004. (Pubitemid 41350895)
10. Yan L, Donze JR and Liu L: Inactivated MGMT by O6-benzyl-guanine is associated with prolonged G2/M arrest in cancer cells treated with BCNU. Oncogene 24: 2175-2183, 2005.
11. Jin S, Shen JN, Wang J, Huang G and Zhou JG: Oridonin induced apoptosis through AKT and MAPKS signaling pathways in human osteosarcoma cells. Cancer Biol Ther 6: 261-268, 2007.
12. Liu YQ, You S, Tashiro S, Onodera S and Ikejima T: Activation of phosphoinositide 3-kinase, protein kinase c, and extracellular signal-regulated kinase is required for oridonin-enhanced phagocytosis of apoptotic bodies in human macrophage-like U937 cells. J Pharmacol Sci 98: 361-371, 2005.
13. Zhang CL, Wu LJ, Zuo HJ, Tashiro S, Onodera S and Ikejima T: Cytochrome c release from oridonin-treated apoptotic A375-S2 cells is dependent on p53 and extracellular signal-regulated kinase activation. J Pharmacol Sci 96: 155-163, 2004.
14. Liu YQ, Mu ZQ, You S, Tashiro S, Onodera S and Ikejima T: Fas/FasL signaling allows extracelluar-signal regulated kinase to regulate cytochrome c release in oridonin-induced apoptotic U937 cells. Biol Pharm Bull 29: 1873-1879, 2006.
15. Zhang CL, Wu LJ, Tashiro S, Onodera S and Ikejima T: Oridonin induces a caspase-independent but mitochondria-and MAPK-dependent cell death in the murine fibrosarcoma cell line L929. Biol Pharm Bull 27: 1527-1531, 2004. (Pubitemid 41701633)
16. Li D, Wu LJ, Tashiro S, Onodera S and Ikejima T: Oridonin-induced A431 cell apoptosis partially through blockage of the RAS/RAF/ERK signal pathway. J Pharmacol Sci 103: 56-66, 2007.
17. Chaparro M, Gonzalez Moreno L, Trapero-Marugan M, Medina J and Moreno-Otero R: Review article: pharmacological therapy for hepatocellular carcinoma with sorafenib and other oral agents. Aliment Pharmacol Ther 28: 1269-1277, 2008.
18. Cheng Y, Qiu F, Ye YC, Tashiro S, Onodera S and Ikejima T: Oridonin induces G2/M arrest and apoptosis via activating ERK-p53 apoptotic pathway and inhibiting PTK-RAS-RAF-JNK survival pathway in murine fibrosarcoma L929 cells. Arch Biochem Biophys 490: 70-75, 2009.
19. Shen Y and White E: P53-dependent apoptosis pathways. Adv Cancer Res 82: 55-84, 2001.